A recent clinical trial, funded by a pharmaceutical company and published in The Lancet, suggests a lab-made rabies immunoglobulin could replace animal and human-derived versions in India’s public hospitals. This shift promises a safer, more affordable option for preventing rabies after dog bites. Post navigation Parliamentary panel slams ‘perpetual tolling’ on national highways In a 1st in India, Goa to negotiate lower prices for life-saving therapies